Founded on the September 18th, 2017 and headquartered near Düsseldorf, Germany, Priavoid GmbH is a biopharmaceutical company focused on the development of innovative disease-modifying therapies for patients with severe neurological disorders. Priavoid’s pharmaceutical development programs are exclusively based on D-enantiomeric peptides (all-D-peptides).

The most advanced drug in our pipeline is named PRI-002. The orally available clinical stage drug candidate directly eliminates toxic amyloid-beta (Aß) oligomers for the causal treatment of Alzheimer’s disease (AD).   Oral administration resulted in significantly improved cognitive read out in three different in vivo models.

The First-in-Human phase I single ascending dose (SAD) and the multiple ascending dose (MAD) clinical trials with PRI-002 were successfully completed, demonstrating excellent safety, tolerability and pharmacokinetic profiles. The MAD part included administration of PRI-002 up to 320mg/subject/day orally for 28 days to healthy volunteers.

The orally available drug candidate PRI-003 has accomplished successful PoC in an in vivo disease model of Amyotrophic lateral sclerosis (ALS). Priavoid accelerates this research program towards clinical development.

PRI-004 is our drug candidate for the treatment of neuropathic pain. The program is ready to initiate clinical research.

Priavoid’s development pipeline is targeting additional orphan and non-orphan CNS disorders caused by misfolded peptides, incl. tauopathies, Huntington’s disease (HD), and Parkinson’s disease (PD).